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The novel approach in the treatment of complex multifactorial diseases, such as
neurodegenerative disorders and cancer, requires a development of efficient multi-
targeting oriented drugs. Since oxidative stress significantly contributes to the
pathogenesis of cancer and neurodegenerative disorders, potential drug candidates
should possess good antioxidant properties. Due to promising biological activities shown
for structurally related (1,3-thiazol-2-yl)hydrazones, a focused library of 12 structurally
related benzylidene-based (1,3-selenazol-2-yl)hydrazones was designed as potential
multi-targeting compounds. Monoamine oxidases (MAO) A/B inhibition properties of this
class of compounds have been investigated. Surprisingly, the p-nitrophenyl-substituted
(1,3-selenazol-2-yl)hydrazone 4 showed MAO B inhibition in a nanomolar concentration
range (IC50 = 73 nM). Excellent antioxidant properties were confirmed in a number
of different in vitro assays. Antiproliferative activity screening on a panel of six human
solid tumor cell lines showed that potencies of some of the investigated compounds
was comparable or even better than that of the positive control 5-fluorouracil. In-silico
calculations of ADME properties pointed to promising good pharmacokinetic profiles of
investigated compounds. Docking studies suggest that some compounds, compared to
positive controls, have the ability to strongly interact with targets relevant to cancer such
as 5′-nucleotidase, and to neurodegenerative diseases such as the small conductance
calcium-activated potassium channel protein 1, in addition to confirmation of inhibitory
binding at MAO B.
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INTRODUCTION
After selenium was recognized as essential element to mammals,
awareness about selenium toxicity changed in great extent
and nowadays it is considered as micronutrient used in
disease prevention and treatment by selenium supplementation
(Weekley and Harris, 2013). Selenium chemistry is more similar
to sulfur, than to lighter chalcogen element—oxygen. The most
important difference among two heavier chalcogens, which
is related to their redox chemistry, is known as “selenium
paradox”—selenium’s ability to undergo fast oxidation and then
reversible reduction (Reich and Hondal, 2016). Also, almost all
chemical reactions involving selenium are faster in comparison
to the similar reactions with sulfur. For example, replacement
of selenium with sulfur in selenium-based enzymes reduced
catalytic activity, while opposite trend was found for Cys-
containing enzymes after isosteric replacement of sulfur with
selenium atom (Reich and Hondal, 2016).
Selenocysteine, selenium analog of cysteine, is the 21st
amino acid incorporated in 25 Se-proteins encoded within
human genome, while more than 30 Se-proteins have been
identified in mammals (Cardoso et al., 2015). Numerous
biological functions of selenium are expressed mainly via
its role in catalytic reactions since it is constituent of active
site of Se-proteins. Selenium is essential for the brain and
participates in the pathology of neurodegenerative disorders,
amyotrophic lateral sclerosis and epilepsy (Solovyev, 2015).
Some Se-proteins are involved in processes such as thyroid
hormones metabolism, spermatogenesis, and Se-proteins
biosynthesis, while others participate in antioxidant defense
and redox state regulation (Roman et al., 2014). Se-proteins
with antioxidant function protect directly against oxidative
stress or indirectly via regeneration and activation of low
molecular weight antioxidants, when provided at low nutritional
levels. On the other hand, elevated doses of selenium result in
manifestation of its pro-oxidant, growth inhibition and cytotoxic
properties (Fernandes and Gandin, 2015). Apart from usage
of selenium compounds in diseases prevention by selenium
supplementation, developing of synthetic organoselenium
compounds as well as their metal complexes is subject of
research in the field of medicinal chemistry. The potential of
synthetic selenium compounds in medicinal chemistry include
antioxidant, antitumor, antiviral, antimicrobial, anti-infective,
anti-inflammatory, antiparasitic, antidiabetic, antimalarial,
neuroprotective, antihypersensitive, and cardiotonic agents
as well as enzyme inhibitors and immunomodulators
(Karvekar et al., 2007; Akhoon et al., 2015; Filipovic´ et al.,
2016).
Selenium-containing heterocycles represent an interesting
class of compounds because of both, interesting chemical
properties and pharmaceutical applications (Mugesh et al.,
2001). Based on the advantages related to the presence of
selenium and the importance of heterocycles in the field of
medicinal chemistry, synthesis of organoselenium compounds
containing 1,3-selenazole ring, as well as study of their
biological application, is in focus of current research. Many
functionalized 1,3-selenazole rings are important constituent of
pharmacologically active compounds (Zhao et al., 2013). 1,3-
Selenazole derivatives are known to inhibit the synthesis of
nitric acid (Ueda et al., 2005) and they act as antagonists for
histamine H2 receptors (van der Goot et al., 1994). They also
display anticancer (Zaharia et al., 2013; Zhao et al., 2013; Hong
et al., 2015), antimicrobial (Al-Rubaie et al., 2014; Łaczkowski
et al., 2016; Mbaveng et al., 2016; Filipovic´ et al., 2017),
and xantine oxidase inhibitory activities (Šmelcerovic´ et al.,
2017).
The biological activity (1,3-selenazol-2-yl)hydrazones
is relatively unexplored area of research: only two studies
dealing with anticancer (Zaharia et al., 2013; Zhao et al.,
2013) and three studies dealing with antimicrobial activity
(Łaczkowski et al., 2016; Mbaveng et al., 2016; Filipovic´
et al., 2017) of (1,3-selenazol-2-yl)hydrazones have been
published up to now. Despite the fact that (1,3-selenazol-2-
yl)hydrazones are structurally related to their sulfur analogs,
which are well known as potent monoamine oxidases (MAO)
A/B inhibitors (Secci et al., 2012; Carradori et al., 2018;
Oncü Can et al., 2018; Tripathi et al., 2018) with good
antioxidative properties, there is no study of MAO A/B
inhibition capacity of this class of selenium compounds to the
best of our knowledge. Our recent study on pyridine-based (1,3-
chalcogenazole-2-yl)hydrazones revealed that selenium-based
compounds exhibited lower toxicity and superior antioxidant
properties in comparison to their sulfur analogs (Filipovic´ et al.,
2017).
Modern treatment of complex multifactorial diseases,
such as cancer and neurodegeneration, is transferred from
development of single-targeting agents to simultaneous
interactions with multiple targets via multi-targeting agents
(MTAs) (Talevi, 2015). Both, neurodegeneration and cancer
have their own molecular targets which need to be considered
for design of novel MTAs. In the case of neurodegeneration,
monoamine oxidases (MAO) A/B are suggested as one
of the main targets for design of novel MTAs (Ramsay
et al., 2016), while novel MTAs for the treatment of
cancer are focused on targets like DNA and cancer-related
proteins (Fu et al., 2017). However, since oxidative stress
significantly contributes to the pathogenesis of cancer and
neurodegeneration, novel effective MTAs should possess also
good antioxidant properties (Lü et al., 2010; Carradori et al.,
2018).
Since biological activity is influenced by the structural and
molecular properties, particularly electronic properties, future
prospects for design and development of new compounds
with potential targeted biological activity can be based on
the information obtained from experimental and theoretical
results. In this work we designed a focused library of 12
structurally related benzylidene-based (1,3-selenazol-2-
yl)hydrazones (Figure 1) and tested their antiproliferative,
antioxidative and MAO A/B inhibition properties. In order
to evaluate the multi-targeting properties of investigated
compounds to both, Parkinson’s disease and cancer, possible
targets for the most active compounds were suggested
by the similarity ensemble approach (SEA) (Keiser et al.,
2007).
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FIGURE 1 | Synthesis of benzylidene-based (1,3-selenazol-2-yl)
hydrazones studied in this work.
MATERIALS AND METHODS
Chemicals and Drugs
Potassium selenocyanate (99%, Cat. No. 201980500),
hydrazine monohydrate (100%, Cat. No. 196711000),
2-bromoacetophenone (98%, Cat. No. 152010250), and
2-bromo-4′-methylacetophenone (97%, 170390250) were
obtained from Acros Organics. Benzaldehyde (≥99.5%,
Cat. No. 418099), 2-nitrobenzaldehyde (98%, Cat. No.
N10802), 3-nitrobenzaldehyde (99%, Cat. No. N10845) and
4-nitrobenzaldehyde (98%, 130176), diphenyl-1-picrylhydrazyl
(DPPH, Cat. No. D9132), 2,2′-azobis(2-methylpropionamidine)
dihydrochloride (AAPH; 97%, Cat. No. 440914), and fluorescein
sodium salt (Cat. No. 46960-25G-F) were obtained from Sigma.
2-Bromo-4′-methoxyacetophenone (97%, Cat. No. CD00356EB)
was obtained from Maybridge. Acetone selenosemicarbazone
and the precursors, benzaldehyde selenosemicarbazone and
2-, 3-, and 4-nitrobenzaldehyde selenosemicarbazones, were
synthesized according reported literature procedures (Huls and
Renson, 1956). All solvents used in synthesis (reagent grade)
were obtained from commercial suppliers and used without
further purification.
Instruments
Melting points were determined using an Electro thermal IA
9200 digital melting point apparatus and are uncorrected.
Elemental analyses (C, H, N) were performed by the standard
micromethods using the ELEMENTAR Vario EL III CHNS/O
analyzer. Elemental analyses are within±0.4%, confirming>95%
purity. Infra-red (IR) spectra were recorded on a Thermo
Scientific Nicolet 6700 FT-IR spectrometer by the Attenuated
Total Reflection (ATR) technique in the region 4,000–400 cm−1.
Abbreviations used for IR spectra: vs, very strong; s, strong;
m, medium; w, weak. The NMR spectra (1D and 2D) were
recorded on a Bruker Avance 500. Chemical shifts are given
on δ scale relative to tetramethylsilane. Abbreviations used for
NMR spectra: s, singlet; br. s, broad singlet; d, doublet; t,
triplet; dd, double of doublets; m, multiplet; ovlp., overlapping.
Atom numbering is given in Figure 1. BioTek’sPowerWave XS
Tecan Infinite R© M1000 PRO multimode reader was used for
measurment of fluorescence intensity in MAO assay.
General Procedure for Preparation of
Benzylidene-Based
(1,3-Selenazol-2-yl)Hydrazones
All compounds were prepared by the reaction of corresponding
selenosemicarbazones and α-bromocarbonyl derivatives.
Selenosemicarbazones (0.4 mmol) were suspended in 20mL
of water/EtOH (1:1, v/v) solvent mixture and 0.4 mmol of
α-bromocarbonyl derivatives were added. The reaction mixtures
were refluxed with stirring for 4 h. After completion of the
reactions, monitored by TLC (ethyl acetate/hexane 1:1, v/v),
the obtained precipitates were filtered off and washed with cold
EtOH. The crude products were recrystallized from acetonitrile.
2-(2-Benzylidenehydrazinyl)-4-phenyl-1,3-selenazole
(1)
Yield: 0.10 g (77%). Mp: 178–180◦C. IR (ATR, νmax/cm−1): 3,298
(w), 3,139 (w), 3,058 (w), 2,959 (w), 2,852 (w), 1,602 (w), 1,559
(vs), 1,483 (m), 1,435 (m), 1,347 (w), 1,263 (s), 1,120 (m),
1,040 (w), 1,023 (w), 934 (w), 754 (m), 710 (m), 689 (m), 507
(w). 1H NMR (500.26 MHz, DMSO-d6) δ: 7.29 (t, 1H, H–
C14, J = 7.2Hz), 7.34–7.48 (m, 5H, H–C4, H–C3 = H–C5,
H–C13 = H–C15), 7.66 (d, 2H, H–C2 = H–C6, J = 7.2Hz),
7.69 (s, 1H, H–C9), 7.85 (d, 2H, H–C12 = H–C16, J = 7.2Hz),
8.09 (s, 1H, H–C7), 12.27 (br. s, 1H, H–N2). 13C NMR (126.0
MHz, DMSO-d6) δ: 107.95 (C9), 126.45 (C12 = C16), 126.97
(C2= C6), 128.01 (C14), 129.25 (C13= C15), 129.53 (C3= C5),
130.03 (C4), 135.04 (C1), 136.10 (C11), 142.88 (C7), 151.62
(C10), 171.93 (C8). Anal. Calcd. for C16H13N3Se (%): C, 58.90;
H, 4.02; N, 12.88. Found: C, 58.62; H, 4.22; N, 12.67%.
2-(2-Benzylidenehydrazinyl)-4-(4-methoxyphenyl)-
1,3-selenazole (1-OMe)
Yield: 0.13 g (91%). Mp: 180–182◦C. IR (ATR, νmax/cm−1):
3,140 (m), 3,062 (m), 3,004 (m), 2,958 (m), 2,905 (m), 2,836 (m),
1,612 (m), 1,572 (vs), 1,490 (s), 1,436 (m), 1,355 (m), 1,320 (m),
1,300 (m), 1,265 (m), 1,246 (s), 1,175 (m), 1,124 (m), 1,027 (s),
937 (w), 832 (m), 755 (m), 694 (m), 610 (w), 528 (w). 1H NMR
(500.26 MHz, DMSO-d6) δ: 3.78 (s, 3H, H–C17), 6.96 (d, 2H,
H–C13 = H–C15, J = 8.7Hz), 7.39 (dd, 1H, H–C4, J = 8.3Hz,
J = 6.2Hz), 7.44 (t, 2H,H–C3 = H–C5, J = 7.4Hz), 7.51 (s, 1H,
H–C9), 7.67 (d, 2H, H–C2= H–C6, J = 7.4Hz), 7.78 (d, 2H, H–
C12 = H–C16, J = 8.7Hz), 8.09 (s, 1H, H–C7), 12.24 (br. s, 1H,
H–N2). 13CNMR (126.0 MHz, DMSO-d6) δ: 55.68 (C17), 105.34
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(C9), 114.50 (C12=C16), 126.86 (C13=C15), 127.65 (C2=C6),
128.85 (C11), 129.42 (C3= C5), 129.89 (C4), 135.00 (C1), 142.80
(C7), 150.78 (C10), 159.21 (C14), 171.70 (C8). Anal. Calcd. for
C17H15N3OSe (%): C, 57.31; H, 4.24; N, 11.79. Found: C, 57.64;
H, 4.35; N, 11.92%.
2-(2-Benzylidenehydrazinyl)-4-(p-tolyl)-1,3-
selenazole (1-Me)
Yield: 0.07 g (51%). Mp: 174–176◦C. IR (ATR, νmax/cm−1): 3,143
(m), 3,057 (m), 2,911 (m), 2,859 (m), 1,617 (m), 1,576 (vs), 1,561
(vs), 1,492 (m), 1,436 (m), 1,264 (m), 1,039 (m), 823 (m), 751 (m),
689 (m), 611 (w). 1H NMR (500.26 MHz, DMSO-d6) δ: 2.31 (s,
3H, H–C17), 7.21 (d, 2H, H–C13 = H–C15,J = 8.0Hz), 7.39 (t,
1H, H–C4, J = 7.2Hz), 7.44 (t, 2H, H–C3 = H–C5, J = 7.4Hz),
7.59 (s, 1H, H–C9), 7.67 (d, 2H,H–C2 = H–C6, J = 7.4Hz),
7.72 (d, 2H, H–C12 = H–C16, J = 8.0Hz), 8.09 (s, 1H, H–C7),
12.26 (br. s, 1H, H–N2). 13C NMR (126.0 MHz, DMSO-d6) δ:
21.37 (C17), 106.71 (C9), 126.29 (C12= C16), 126.87 (C2= C6),
129.43 (C13 = C15), 129.72 (C3 = C5), 129.91 (C4), 133.32
(C11), 134.98 (C1), 137.17 (C14), 142.80 (C7), 151.24 (C10),
171.73 (C8). Anal. Calcd. for C17H15N3Se (%): C, 60.00; H, 4.44;
N, 12.35. Found: C, 60.23; H, 4.67; N, 12.59%.
2-(2-(2-Nitrobenzylidene)hydrazinyl)-4-phenyl-1,3-
selenazole (2)
Yield: 0.083 g (56%).Mp: 183–184◦C.IR (ATR, νmax/cm−1): 3,164
(w), 3,115 (w), 3,047 (w), 2,963 (w), 2,851 (m), 2,792 (m), 1,580
(vs), 1,518 (vs), 1,481 (m), 1,438 (m), 1,341 (s), 1,297 (m), 1,266
(s), 1,128 (m), 1,043 (m), 1,023 (w), 918 (w), 904 (w), 847 (w), 780
(w), 747 (w), 706 (m), 660 (m).1HNMR (500.26MHz, DMSO-d6)
δ: 7.30 (t, 1H, H–C14, J = 7.3Hz), 7.39 (t, 2H, H–C13=H–C15,
J = 7.7Hz), 7.61 (m, 1H, H–C5), 7.74 (s, 1H, H–C9), 7.78 (t. 1H,
H–C4, J = 7.7Hz), 7.84 (d, 2H, H–C12 = H–C16,J = 7.4Hz),
8.01 (d, 1H, H–C3, J = 0.7Hz), 8.03 (s. 1H, H–C6), 8.45 (s, 1H,
H–C7).13C NMR (126.0 MHz, DMSO-d6) δ: 108.77 (C9), 125.35
(C3), 126.45 (C12 = C16), 128.13 (C14), 128.29 (C6), 129.10
(C1), 129.29 (C13 = C15), 130.49 (C5), 134.16 (C4), 135.86
(C11), 137.93 (C7), 148.13 (C2), 151.39 (C10), 171.81 (C8).Anal.
Calcd. for C16H12N4O2Se (%): C, 51.76; H, 3.26; N, 15.09. Found:
C, 52.32; H, 2.60; N, 15.14%.
4-(4-Methoxyphenyl)-2-(2-(2-
nitrobenzylidene)hydrazinyl)-1,3-selenazole (2-OMe)
Yield: 0.104 g (66%), Mp: 165–166◦C. IR (ATR, νmax/cm−1):
3,108 (w), 3,030 (w), 2,954 (w), 2,901 (w), 2,830 (m), 2,654 (m),
2,324 (w), 1,603 (w), 1,569 (s), 1,516 (s), 1,493 (m), 1,441 (m),
1,364 (w), 1,337 (s), 1,307 (m), 1,242 (s), 1,169 (m), 1,126 (m),
1,040 (m), 918 (w), 837 (m), 785 (w), 745 (w), 715 (w). 1H NMR
(500.26 MHz, DMSO-d6) δ: 3.77 (s, 3H, H–C17), 6.95 (d, 2H,
H–C13 = H–C15, J = 8.8Hz), 7.54 (s, 1H, H–C9), 7.60 (m,
1H, H–C5), 7.74–7.80 (m, 3H, H–C4 and H–C12 = H–C16),
8.01 (d, 1H, H–C3, J = 1.0Hz), 8.02 (d, 1H, H–C6, J = 1.0Hz),
8.45 (s, 1H, H–C7). 13C NMR (126.0 MHz, DMSO-d6) δ: 55.79
(C17), 106.30 (C9), 114.63 (C13 = C15), 125.34 (C3), 127.77
(C12 = C16), 128.27 (C6), 128.67 (C11), 129.14 (C1), 130.44
(C5), 134.15 (C4), 137.95 (C7), 148.12 (C2), 150.82 (C10), 159.38
(C14), 171.73 (C8). Anal. Calcd. for C17H14N4O3Se (%): C, 50.88;
H, 3.52; N, 13.96. Found: C, 51.71; H, 1.95; N, 13.98%.
2-(2-(2-Nitrobenzylidene)hydrazinyl)-4-(p-tolyl)-1,3-
selenazole (2-Me)
Yield: 0.108 g (70%). Mp: 170–171◦C. IR (ATR, νmax/cm−1):
3,305 (w), 3,156 (w), 3,116 (w), 3,074 (w), 2,971 (w), 2,917 (w),
2,858 (w), 1,569 (vs), 1,521 (vs), 1,439 (m), 1,337 (s), 1,294 (m),
1,262 (m), 1,179 (m), 1,125 (m), 1,038 (m), 922 (w), 846 (w), 828
(w), 748 (w), 730 (w), 709 (w). 1HNMR (500.26MHz, DMSO-d6)
δ: 2.30 (s, 3H, H–C17), 7.19 (d, 2H,H–C13=H–C15, J = 8.1Hz),
7.58–7.63 (m, 1H, H–C5), 7.64 (s, 1H, H–C9), 7.72 (d, 2H, H–
C12=H–C16, J= 8.1Hz), 7.75–7.80 (m, 1H, H–C4), 8.01 (d, 1H,
H–C3, J = 1.0Hz), 8.02 (d, 1H, H–C6, J = 1.0Hz), 8.45 (s, 1H,
H–C7). 13C NMR (126.0 MHz, DMSO-d6) δ: 20.84 (C17), 107.03
(C9), 124.73 (C3), 125.77 (C12= C16), 127.66 (C6), 128.50 (C1),
129.23 (C13 = C15), 129.84 (C5), 132.55 (C11), 133.53 (C4),
136.80 (C14), 137.30 (C7), 147.50 (C2), 150.71 (C10), 171.21
(C8). Anal. Calcd. for C17H14N4O2Se (%): C, 53.00; H, 3.66; N,
14.54. Found: C, 52.59; H, 3.18; N, 14.36%.
2-(2-(3-Nitrobenzylidene)hydrazinyl)-4-phenyl-1,3-
selenazole (3)
Yield: 0.108 g (73%). Mp: 216–218◦C. IR (ATR, νmax/cm−1):
3,163 (w), 3,062 (w), 2,962 (w), 2,862 (m), 2,804 (w), 1,608 (w),
1,580 (s), 1,526 (vs), 1,482 (m), 1,453 (m), 1,345 (s), 1,268 (m),
1,131 (m), 1,093 (w), 928 (w), 734 (m), 704 (m), 673 (w). 1HNMR
(500.26 MHz, DMSO-d6) δ: 7.30 (t, 1H, H–C14, J = 7.3Hz), 7.39
(t, 2H, H–C13=H–C15, J = 7.6Hz), 7.71 (t, 2H, ovlp. H–C5 and
H–C9, J = 7.9Hz), 7.84 (d, 2H, H–C12 = H–C16, J = 7.4Hz),
8.08 (d, 1H, H–C6, J = 7.8Hz), 8.19 (m, 2H, ovlp. H–C4 and H–
C7), 8.45 (s, 1H, H–C2), 12.54 (s, 1H, H–N2).13C NMR (126.0
MHz, DMSO-d6) δ: 107.71 (C9), 120.40 (C2), 123.49 (C4), 125.83
(C12 = C16), 127.52 (C14), 128.68 (C13 = C15), 130.49 (C5),
132.31 (C6), 135.23 (C11), 136.33 (C3), 140.02 (C7), 148.34 (C1),
150.86 (C10), 171.30 (C8). Anal. Calcd. for C16H12N4O2Se (%):
C, 51.76; H, 3.26; N, 15.09. Found: C, 51.54; H, 3.00; N, 15.11%.
4-(4-Methoxyphenyl)-2-(2-(3-
nitrobenzylidene)hydrazinyl)-1,3-selenazole (3-OMe)
Yield: 0.112 g (70%). Mp: 201–203◦C. IR (ATR, νmax/cm−1):
3,161 (w), 3,049 (w), 2,958 (m), 2,829 (m), 2,371 (w), 1,581 (s),
1,523 (vs), 1,489 (m), 1,452 (m), 1,330 (s), 1,320m), 1,300 (m),
1,272 (m), 1,245 (s), 1,174 (m), 1,131 (s), 1,032 (m), 930 (w), 834
(m), 752 (w), 731 (w), 675 (w).1H NMR (500.26 MHz, DMSO-
d6) δ: 3.77 (s, 3H, H–C17), 6.95 (m, 2H, H–C13 = H–C15), 7.52
(s, 1H, H–C9), 7.71 (t, 1H, H–C5, J = 8.0Hz), 7.76 (m, 2H,
H–C12 = H–C16), 8.08 (m, 1H, H–C6), 8.19 (m, 2H, ovlp. H–
C4 and H–C7), 8.45 (m, 1H, H–C2), 12.44 (s, 1H, H–N2).13C
NMR (126.0MHz, DMSO-d6) δ: 55.16 (C17), 105.05 (C9), 114.00
(C13 = C15), 120.37 (C2), 123.44 (C4), 127.13 (C12 = C16),
127.98 (C11), 130.47 (C5), 132.28 (C6), 136.38 (C3), 140.00 (C7),
148.33 (C1), 150.60 (C10), 158.75 (C14), 171.21 (C8).Anal. Calcd.
for C17H14N4O3Se (%): C, 50.88; H, 3.52; N, 13.96. Found: C,
51.55; H, 3.17; N, 14.12%.
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2-(2-(3-Nitrobenzylidene)hydrazinyl)-4-(p-tolyl)-1,3-
selenazole (3-Me)
Yield: 0.106 g (69%),Mp: 203–206◦C.IR (ATR, νmax/cm−1): 3,154
(w), 3,111 (w), 3,046 (w), 2,912 (m), 2,856 (m), 2,363 (w), 1,602
(w), 1,575 (s), 1,523 (vs), 1,486 (m), 1,448 (m), 1,342 (s), 1,266
(m), 1,177 (w), 1,130 (m), 1,039 (m), 925 (w), 830 (w), 735 (w),
674 (w). 1H NMR (500.26 MHz, DMSO-d6) δ: 2.30 (s, 3H, H–
C17), 7.19 (d, 2H, H–C13= H–C15, J = 8.0Hz), 7.62 (s, 1H, H–
C9), 7.71 (m, 3H, ovlp. H–C5 and H–C12=H–C16), 8.08 (d, 1H,
H–C6, J = 7.8Hz), 8.18 (dd, 1H, H–C4, J = 2.3Hz, J = 0.8Hz),
8.20 (s,1H, H–C7), 8.44 (m, 1H, H–C2), 12.46 (s, 1H, H–N2).13C
NMR (126.0MHz, DMSO-d6) δ: 20.82 (C17), 106.54 (C9), 120.37
(C2), 123.44 (C4), 125.74 (C12 = C16), 129.21 (C13 = C15),
130.45 (C5), 132.28 (C6), 132.50 (C11), 136.35 (C3), 136.78
(C14), 140.06 (C7), 148.32 (C1), 150.60 (C10), 171.22 (C8). Anal.
Calcd. for C17H14N4O2Se (%): C, 53.00; H, 3.66; N, 14.54. Found:
C, 53.23; H, 3.36; N, 14.59%.
2-(2-(4-Nitrobenzylidene)hydrazinyl)-4-phenyl-1,3-
selenazole (4)
Yield: 0.102 g (69%). Mp: 228–230◦C. IR (ATR, νmax/cm−1): 3290
(m), 3,110 (w), 1,584 (w), 1,554 (m), 1,511 (s), 1,440 (w), 1,321
(m), 1,282 (m), 1,146 (w), 1,040 (w), 920 (w), 847 (s), 774 (w), 711
(m), 689 (w).1H NMR (500.26 MHz, DMSO-d6) δ: 7.30 (t, 1H,
H–C14, J = 7.3Hz), 7.39 (t, 2H, H–C13 = H–C15, J = 7.6Hz),
7.75 (s, 1H, H–C9), 7.84 (d, 2H, H–C12 = H–C16, J = 7.3Hz),
7.88 (d, 2H, H–C2=H–C6, J = 8.9Hz), 8.16 (s, 1H, H–C7), 8.26
(d, 2H, H–C3 = H–C5, J = 8.9Hz), 12.65 (s, 1H, H–N2). 13C
NMR (126.0 MHz, DMSO-d6) δ: 107.96 (C9), 124.14 (C3 = C5),
125.76 (C12 = C16), 126.99 (C2 = C6), 127.47 (C14), 128.61
(C13 = C15), 135.16 (C11), 139.81 (C7), 140.75 (C1), 147.14
(C4), 150.88 (C10), 171.14 (C8). Anal. Calcd. for C16H12N4O2Se
(%): C, 51.76; H, 3.26; N, 15.09. Found: C, 51.76; H, 3.05; N,
15.10%.
4-(4-Methoxyphenyl)-2-(2-(4-
nitrobenzylidene)hydrazinyl)-1,3-selenazole (4-OMe)
Single crystals suitable for X-ray diffraction analysis were
obtained from acetonitrile solution after 2 days. Yield: 0.119 g
(74%). Mp: 208–211◦C. IR (ATR, νmax/cm−1): 2,661 (w), 1,587
(m), 1,565 (m), 1,532 (w), 1,512 (s), 1,488 (m), 1,454 (m), 1,376
(w), 1,341 (s), 1,248 (m), 1,172 (m), 1,142 (m), 1,106 (m), 1,044
(m), 1,022 (m), 925 (m), 908 (w), 876 (w), 840 (m), 747 (w),
684 (w). 1H NMR (500.26 MHz, DMSO-d6) δ: 3.78 (s, 3H, H–
C17), 6.95 (d, 2H,H–C13 = H–C15, J = 8.8Hz), 7.56 (s, 1H,
H–C9), 7.76 (d, 2H, H–C12 = H–C16, J = 8.7Hz), 7.78 (d,
2H, H–C2 = H–C6, J = 8.8Hz), 8.16 (s, 1H, H–C7), 8.26
(d, 2H, H–C3 = H–C5, J = 8.8Hz) 12.58 (s, 1H, H–N2).13C
NMR (126.0MHz, DMSO-d6) δ: 55.15 (C17), 105.49 (C9), 113.99
(C13 = C15), 124.18 (C3 = C5), 127.02 (C2 = C6), 127.12
(C12 = C16), 127.94 (C11), 139.84 (C7), 140.87 (C1), 147.16
(C4), 150.88 (C10), 158.76 (C14), 171.18 (C8). Anal. Calcd. for
C17H14N4O3Se (%): C, 50.88; H, 3.52; N, 13.96. Found: C, 50.80;
H, 3.30; N, 14.02%.
2-(2-(4-Nitrobenzylidene)hydrazinyl)-4-(p-tolyl)-1,3-
selenazole (4-Me)
Single crystals suitable for X-ray diffraction analysis were
obtained from acetonitrile solution after 3 days. Yield: 0.111 g
(72%), Mp: 228–230◦C. IR (ATR, νmax/cm−1): 3,110 (w), 2,922
(w), 2,668 (m), 1,608 (m), 1,587 (s), 1,565 (s), 1,513 (vs), 1,456
(s), 1,409 (w), 1,374 (w), 1,341 (vs), 1,320 (s), 1,285 (s), 1,177 (w),
1,144 (m), 1,107 (w), 1,042 (m), 924 (w), 907 (w), 849 (w), 828
(m), 746 (w). 1H NMR (500.26 MHz, DMSO-d6) δ: 2.30 (s, 3H,
H–C17), 7.19 (d, 2H, H–C13 = H–C15, J = 8.0Hz), 7.65 (s, 1H,
H–C9), 7.72 (d, 2H, H–C12 = H–C16, J = 8.1Hz), 7.88 (d, 2H,
H–C2 = H–C6, J = 8.9Hz), 8.16 (s, 1H, H–C7), 8,25 (d, 2H,H–
C3 = H–C5, J = 8.9Hz), 12.58 (s, 1H, H–N2). 13C NMR (126.0
MHz, DMSO-d6) δ: 20.83 (C17), 107.10 (C9), 124.19 (C3 = C5),
125.76 (C12 = C16), 127.03 (C2 = C6), 129.23 (C13 = C15),
132.48 (C11), 136.83 (C14), 139.80 (C7), 140.86 (C1), 147.17
(C4), 150.56 (C10), 171.19 (C8). Anal. Calcd. for C17H14N4O2Se
(%): C, 53.00; H, 3.66; N, 14.54. Found: C, 53.37; H, 3.22; N,
14.70%.
X-Ray Crystallography
Data collection for single crystals of 4-Me and 4-OMe was
performed at room temperature on an Oxford Diffraction
Xcalibur Nova R diffractometer with a microfocusing Cu tube
(λ= 1.54179 Å). Data reduction and cell refinement were carried
out using the CRYSALIS PRO software (Oxford Diffraction
Ltd.,, 2009). Structures were solved by direct methods with
SIR2014 (Burla et al., 2015) and refined by a full matrix least-
squares refinement based on F2, with SHELXL (Sheldrick, 1997).
Molecular illustrations were prepared with ORTEP-3 (Farrugia,
1997) and MERCURY (Macrae et al., 2008) included into the
WinGX package (Farrugia, 1999). Calculations of molecular
geometries and crystal packing parameters were performed
with PLATON (Spek, 2009). Hydrogen atoms of the phenyl
rings and of the methyl moieties, as well as the H12 for
the compound 4-Me were included in their geometrically
calculated positions and refined according to the riding model,
while the others were located in the Fourier map and refined
freely. CCDC 1494791 and 1494792 contain the supplementary
crystallographic data. These data can be obtained free of charge
via http://www.ccdc.cam.ac.uk/conts/retrieving.html, or from
the Cambridge Crystallographic Data Centre, 12 Union Road,
Cambridge CB2 1EZ, UK; fax: (+44) 1223-336-033; or e-mail:
deposit@ccdc.cam.ac.uk.
Cyclic Voltammetry
The three-electrode system was used, glassy carbon (3mm in
diameter, CHI 104), non-aqueous Ag/Ag+ reference with porous
Teflon tip (CHI 112) and Pt-wire as counter electrode. The
reference electrode was filled with 10mM AgNO3 solution in
0.1M tetrabutylammonium perchlorate (TBAP) in DMSO. The
potential was scanned between −2.0 and +1.0V at scan rate
of 100mV s−1 in anodic positive mode. All measurements
were performed at room temperature. Working solutions
were deaerated for 15min with nitrogen. The voltammograms
were recorded in 0.1M TBAP/DMSO. Concentration of the
compounds was 1mM.
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MAO A/B Inhibition
MAO A and B inhibition capacities were investigated using
a discontinuous fluorimetric assay (Meiring et al., 2013) as
described previously by using human recombinant membrane-
bound MAO purchased from Sigma-Aldrich (Affini et al., 2018).
Briefly, remained enzyme activity with inhibitor, either 1µM
(one-point) or concentrations ranging from 0.0001 to 10µM,
was assessed in the presence of kynuramine [2 × KM, KM = 20
µM (MAO A), KM = 30 µM (MAO B)] in potassium phosphate
buffer (pH 7.4). Reactions were started by addition of enzyme
and stopped by manual addition of sodium hydroxide (2N)
after 20min. Enzyme activity was determined by detection of 4-
hydroxyquinoline (λEx = 320 nm, λEm = 405 nm). Data were
analyzed using GraphPad PRISM 6. For one-point measurements
data were calculated as percentage of control and expressed as
mean ± standard deviation (%). IC50 values are given as mean
within the 95% confidence interval (CI). Data were obtained from
two (one-point measurements) or at least three (IC50 values)
independent experiments, each performed in duplicates.
Assessment of Antioxidant Capacity
DPPH Scavenging Antioxidant Assay
The experiments were performed according to the literature
protocol (Prior et al., 2005). All tested compounds were initially
dissolved in DMSO. The initial concentration of DPPH in
methanol was 6.58 × 10−5 M. A volume of 140 µL of DPPH
solution was placed into a 96-well microplate, and then 10 µL
solution of the tested compounds was added. Pure DMSO (10
µL) was used as the control. The absorbance at 517 nm was
measured after 30min period of incubation in the dark at 25◦C.
The Equation (1) was used for calculation of the scavenging
activity:
Scavenging activity (%) =
Acontrol − Asample
Acontrol
× 100 (1)
where Asample and Acontrol refer to the absorbances at 517 nm
of the sample and control, respectively. IC50 values were
calculated from the graph of scavenging activity against
the concentrations of the samples. IC50 represents the total
antioxidant concentration of the sample which decreases the
amount of the initial DPPH radical by 50%. Ascorbic acid
(vitamin C) was used as positive control (concentration range
10–500µM).
Total Reducing Power (TRP) (Modified Potassium
Ferricyanide Reduction Method)
The mixture containing 0.5mL of phosphate buffer (0.2M,
pH = 6.6), 0.5mL of K3[Fe(CN)6] (1%; w/v) and 0.5mL of the
samples (100–1,500µM) was incubated at 50◦C for 20min. A
volume of 0.5mL of trichloroacetic acid (TCA, 10%; w/v), 0.5mL
of Milli-Q water and 0.5mL of FeCl3 (0.1%; w/v) was added,
followed by intensive vortexing. The absorbance of the resulting
mixture was measured after 60min at 700 nm using phosphate
buffer as blank (Oyaizu, 1986).
Total Antioxidant Capacity (TAOC) (Modified
Phosphomolybdenum Method)
Volume of 0.4mL of sample solution (50–1,000µM) was
mixed with 1.6mL of reagent solution [0.6M H2SO4, 28mM
Na3PO4, and 4mM (NH4)2MoO4] and resulting mixtures
were incubated at 95◦C for 90min. The cooled reaction
mixtures were then centrifuged for 10min (3,000 rpm). The
absorbance of the supernatant solution was measured, 1 h after
centrifugation, at 695 nm against reagent solution as blank.
An increased absorbance in reading in both assays indicated
increased antioxidant power, expressed as EC50 values (the
sample concentration giving absorbance of 0.500 from the
graph of absorbance at 700 nm or 695 nm against compound
concentration) (Prieto et al., 1999).
Oxygen radical Absorbance Capacity (ORAC) Assay
A modification of original protocol was used (Ou et al., 2001).
Stock solutions of fluorescein substrate (5µM) and free radical
generator AAPH (0.5M) were prepared in 75mM potassium
phosphate buffer (pH = 7.4). Volume of 100 µL of sample
solutions or Trolox in DMSO (20µM) were mixed with 1,485µL
of buffer and 15 µL of fluorescein solution. The 30min reaction
at 37◦C was initiated by adding 250 µL of AAPH solution.
Fluorescence conditions were as follows: excitation and emission
wavelengths 485 and 511 nm, respectively, slits 2 nm. The relative
sample ORAC value was expressed as Trolox equivalents (TE).
Antiproliferative Activity
The in vitro antiproliferative activity of investigated compounds
was evaluated against six human solid tumor cell lines: A549
(non-small cell lung), HBL-100, (breast), HeLa (cervix), SW1573
(non-small cell lung), as drug sensitive lines, T-47D (breast) and
WiDr (colon) as drug resistant lines. These cell lines were a kind
gift from Prof. G. J. Peters (VU Medical Center, Amsterdam,
The Netherlands). For selectivity studies, the human fibroblasts
BJ-hTert cell line was used, which was obtained from Dr. R.
Freire (HUC, Tenerife, Canary Islands). Cells were kept in
culture medium under standard conditions: RPMI 1640medium,
fetal bovine serum (5%), glutamine (2mM), penicillin G (100
units/mL) and streptomycin (0.1 mg/mL). Antiproliferative
tests were conducted as described earlier (Skehan et al., 1990;
Miranda et al., 2006). Tested compounds were dissolved in
DMSO at an initial concentration of 40mM. DMSO was
used as negative control (0.25% v/v). Antiproliferative activity
of the compounds was expressed as GI50, which is the
concentration of the compound that inhibits 50% of the culture
growth.
In-silico Studies
The geometries of neutral E-isomeric form for all structures
were optimized at the density functional theory (DFT) level in
the gas phase. Becke-3-Lee-Yang-Par functional (B3LYP) (Lee
et al., 1988; Becke, 1993) and the double split valence 6-31G(d,p)
basis set were used in the calculations (Hariharan and Pople,
1973; Francl, 1982; Rassolov et al., 1998, 2001). Optimized
geometries of the investigated molecules in the gas phase are
shown in Supplementary Figure S1. The gas phase calculated
Frontiers in Chemistry | www.frontiersin.org 6 July 2018 | Volume 6 | Article 247
Elshaflu et al. Selenazolyl-hydrazones as MAO Inhibitors
molecular structures were re-optimized in DMSO using the
Polarisable Continuum Model (Scalmani and Frisch, 2010)
with DFT/B3LYP/6-31G(d,p) method. All quantum chemical
calculations were performed with Gaussian09 program package
(Frisch et al., 2016).
Physicochemical properties, lipophilicity, water solubility,
pharmacokinetics, druglikeness and medicinal chemistry
parameters were determined using the free SwissADME tools
available at website of the Swiss Institute of Bioinformatics
(http://www.swissadme.ch/) (Daina et al., 2017). The
structures were constructed and converted into SMILES
format.
Possible suggestions for targets for compounds were found
using SEA (Keiser et al., 2007), which can relate proteins
by a similarity ensemble approach (initials, SEA) based on
the chemical similarities of ligands. Crystal structures were
obtained from the Protein Data Bank (Berman et al., 2000). The
proteins corresponded to KCNN1 small conductance calcium-
activated potassium channel protein 1 (5wbx, ligand HET-ID
AJY; (3Z)-6-bromo-3-(hydroxyimino)-5-methyl-1,3-dihydro-
2H-indol-2-one) and MAO-B (4crt, ligand HET-ID ASS234;
(E)-N-methyl-N-[[1-methyl-5-[3-[1-(phenylmethyl)piperidin-
4-yl]propoxy]indol-2-yl]methyl]prop-1-en-1-amine), implicated
in neurodegenerative diseases; as well as eukaryotic initiation
factor 4E (1ipb, ligand HET-ID GTA; P1-7-methylguanosine-P3-
adenosine-5′,5′-triphosphate) and 5′-nucleotidase (4h2b, ligand
HET-ID 0XE; 5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-
7-yl beta-D-glucopyranosiduronic acid; Baicalin), implicated
in cancer. All protein structures were determined at high
resolution. Hydrogen atoms were added with Maestro software
(Maestro, 2017). Docking was then performed by AutodockVina
(Trott and Olson, 2010) using a box size of 25 Å in each
dimension; nine modes; energy range of 1 kcal/mol; 1 cpu per
run; exhaustiveness = 16; and 100 runs per ligand and per
protein. In each case, the co-crystallized ligand was taken as a
positive control, and the binding score recorded for it was used
as threshold to determine binders.
RESULTS AND DISCUSSION
Synthesis and Characterization
Twelve benzylidene-based (1,3-selenazol-2-yl)hydrazones were
prepared via Hantzsch type condensation of corresponding
selenosemicarbazones with a series of 4-substituted α-
bromoacetophenones (Figure 1). Compounds 4-OMe and
4-Me crystallized as single crystals suitable for X-ray structural
analysis, which indicated E-configuration of the imine bond
(vide infra).
Synthesis of the compounds 1 and 1-Me was previously
published, but without spectral characterization (Bulka et al.,
1961). Literature data for melting points of 1 and 1-
Me significantly differ from our data (Bulka et al., 1961).
Composition of the compounds was confirmed by elemental
analysis, while NMR and IR spectroscopy were used for structure
elucidation. 1D and 2DNMR spectra are given in Supplementary
Figures S2–S41. The influence of substituents on both phenyl
rings, A and B, on NMR chemical shifts of corresponding
hydrogen and carbon atoms was observed. As expected, in
FIGURE 2 | ORTEP drawings of the molecular structures of 4-Me (A) and 4-OMe (B) with non-H atoms labeling. Displacement ellipsoids are shown at the 50%
probability level and H atoms are drawn as spheres of arbitrary radii. Crystal packing diagrams of 4-Me (C) and 4-OMe (D).
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the 1H NMR spectra of all compounds the signal of H–N2
is the most downfielded. Substitution of the phenyl rings had
negligible influence on chemical shift of a proton from 1,3-
selenazole ring, thus the signal of the proton H–C9 in the 1H
NMR spectra of all compounds appeared in the narrow range
(7.51–7.71 ppm). Introduction of NO2 group on the phenyl
ring A, which has negative inductive and negative resonance
effect, caused downfield shift of signals of all protons in the
ring in comparison to signals of corresponding protons in the
1H NMR spectra of compounds from set 1. Also, chemical shift
of H–C7 protons was affected by this substitution, where for
all compounds from set 2, with NO2 group in ortho-position,
significant shift to lower field was observed. Introduction of
methyl group on the phenyl ring B, which is electron donating
group by induction, caused shielding effect of all protons
from the ring B, where signals of protons H–C13 and H–
C15 were the most affected in the 1H NMR spectra of all
methyl derivatives. The electronic effects of methoxy group,
which is a withdrawer by induction and an electron donor by
resonance, is determined by its position. Since it participates
in delocalization of pi electrons from the phenyl ring B, it
functions as a strong electron donor. This is again mostly
reflected on chemical shifts of H–C13 and H–C15 protons
in the 1H NMR spectra of all methoxy derivatives, where
these protons are shielded and thus their signals are upfielded.
Electronic effects of substituents have the similar impact on
chemical shifts of corresponding carbon atoms in 13C NMR
spectra.
Analysis of Crystal Structures
Relevant crystallographic data for 4-OMe and 4-Me are
summarized in Supplementary Table S1. Molecular structures
of 4-Me and 4-OMe with the atom numberings and crystal
packing motifs are depicted in Figure 2, while selected bond
lengths and bond angles are presented in Table 1. The geometries
of the selenazole rings in both structures reveal no unusual
parameters when compared with the set of related structures
from the current version of CSD (Groom et al., 2016). Analysis
of the interplanar angles defined by the least square plane of the
selenazole ring and the least square planes of both phenyl rings
reveals a certain level of planarity in the structure of 4-OMe
unlike in 4-Me (Supplementary Table S2).Visually this result is
depicted in Figure 3, which displays an overlay of molecular
structures of 4-Me and 4-OMe. The torsion angle Se1–C11–
N12–N13 [−7.3(4)◦ in 4-Me and 1.3(3)◦ in 4-OMe] reveals the
cis-orientation of the N13 with respect to the selenium (and,
consequently, trans-orientations with respect to the N10) in
both structures, which are therefore conformationally prone to
act as N,Se bidentate ligands in possible metal coordination.
Basic crystallographic packing motif in the structure of 4-Me is
a distinct paddle wheel-like centrosymmetric molecular dimer
formed by the hydrogen bond N12– 12···N10i [i = 1–x, y,
1/2–z; d (N12–H): 0.86 Å, d (H···N10): 2.01 Å, d (N12···N10):
2.857(5) Å, angle: 168◦] of the graph set notation R 2,2 (8)
(Figure 2C). The paddlewheel axis running through Se1 and
C11 of both involved molecules is roughly parallel with the
TABLE 1 | Selected experimentally obtained (XRD) and calculated (DFT) bond
lengths (Å) and angles (◦) for 4-Me and 4-OMe.
4-Me (XRD) 4-Me (DFT) 4-OMe (XRD) 4-OMe (DFT)
C7–C9 1.475(5) 1.476 1.475(3) 1.476
C8–C9 1.353(5) 1.368 1.351(3) 1.369
C8–Se1 1.871(5) 1.874 1.873(2) 1.876
C9–N10 1.388(4) 1.391 1.391(2) 1.391
C11–N10 1.300(5) 1.291 1.290(2) 1.292
C11–N12 1.348(5) 1.375 1.361(3) 1.375
C11–Se1 1.872(4) 1.887 1.8808(19) 1.886
C14–N13 1.277(4) 1.290 1.271(3) 1.290
C14–C17 1.451(4) 1.459 1.463(3) 1.459
N12–N13 1.358(4) 1.338 1.354(2) 1.337
N21–O23 1.212(5) 1.232 1.214(3) 1.232
N21–O22 1.218(6) 1.232 1.222(3) 1.232
C9–C8–Se1 111.6(3) 111.16 111.86(16) 111.60
C8–C9–N10 116.0(3) 116.20 116.55(18) 116.20
C8–C9–C7 126.9(3) 125.90 125.85(19) 126.00
N10–C9–C7 117.1(3) 117.90 117.59(17) 117.80
N10–C11–N12 121.3(3) 122.10 124.32(18) 122.00
N10–C11–Se1 115.2(3) 116.30 116.57(15) 116.30
N12–C11–Se1 123.6(3) 121.70 119.11(14) 121.70
N13–C14–C17 121.8(3) 121.20 119.71(19) 121.10
C11–N10–C9 113.4(3) 112.80 112.22(16) 112.80
C11–N12–N13 120.4(3) 120.60 117.09(17) 120.60
C14–N13–N12 115.4(3) 119.10 118.96(17) 119.10
O23–N21–O22 122.6(4) 124.60 123.6(2) 124.60
O23–N21–C20 119.0(4) 117.70 118.4(2) 117.70
O22–N21–C20 118.4(4) 117.70 118.0(2) 117.70
C8–Se1–C11 83.76(16) 83.20 82.79(9) 83.20
FIGURE 3 | Structural superposition of 4-Me (yellow) and 4-OMe (red).
crystallographic a-axis. In the structure of (roughly planar) 4-
OMe crystal packing is guided by a single hydrogen bond N12–
H12···O1ii [ii = 1/2+x, y, 1/2–z; d (N12–H): 0.81(4) Å, d
(H···O1): 2.48 (3) Å, d (N12···O1): 3.202 (3) Å, angle: 150(3)◦]
through which the zig-zag oriented molecules are connected
into the “endless” chains parallel to the crystallographic ac plane
(Figure 2D).
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TABLE 2 | Voltammetric characteristics of the the benzylidene-based (1,3-selenazol-2-yl)hydrazonesa.
Compound EpR(I)b Ip/cv
1/2c EpO(I) Ip/cv
1/2 EpR(II) Ip/cv
1/2 EpO(II) Ip/cv
1/2 EpOx(III) Ip/cv
1/2 E
HOMOd
(CV) EHOMO (DFT)
1 / / / / −1.45 2.1 / / +0.33 39.1 −4.90 −5.34
1-Me / / / / −1.50 2.9 / / +0.28 38.4 −4.85 −5.20
1-OMe / / / / −1.59 2.3 / / +0.31 26.6 −4.88 −5.30
2 −1.26 6.8 −1.27 4.1 −1.46 5.3 −1.39 12.7 +0.40 23.2 −4.97 −5.49
2-Me −1.27 13.2 −1.23 2.3 −1.49 6.6 −1.39 13.9 +0.36 24.0 −4.93 −5.31
2-OMe −1.25 11.3 −1.26 3.6 −1.47 10.6 −1.40 15.5 +0.43 23.0 −5.00 −5.43
3 −1.18 10.7 −1.20 4.2 −1.40 16.8 −1.33 22.2 +0.42 25.7 −4.99 −5.51
3-Me −1.20 4.2 −1.19 5.4 −1.40 17.9 −1.33 4.3 +0.42 18.9 −4.99 −5.32
3-OMe −1.21 13.1 −1.19 4.6 −1.44 14.9 −1.32 21.3 +0.42 20.2 −4.99 −5.45
4 −1.29 25.3 / / −1.38 3.5 −1.32 21.3 +0.41 35.8 −4.98 −5.46
4-Me −1.27 25.3 / / −1.39 2.4 −1.32 19.4 +0.40 34.8 −4.97 −5.28
4-OMe −1.30 26.2 / −1.39 2.2 −1.31 18.9 +0.37 33.5 −4.94 −5.40
a In DMSO containing 0.1M TBAP at v = 100 mV/s.
bE vs ferrocene/ferrocenium couple (Fc/Fc+ ) in V.
c In µA/mM(V/s)1/2; d in eV.
EHOMO = −4.8 – (E – EFc), EFc = +0.23 V.
Cyclic Voltammetry (CV)
All investigated compounds were studied voltammetrically in
DMSO using TBAP as supporting electrolyte. Results of CV
study are given in Table 2. Examples of cyclic voltammograms
of compounds 1–4 are given in Figure 4. In the investigated
potential range (+1.0 to −2.0V), the compounds from set 1
showedmainly one reduction and one oxidation peak. Reduction
peak around −1.40V is caused by reduction of imine group of
the ligand. The peak at around +0.40V can be attributed to
the oxidation of chalcogen or C8 atoms. Both electrochemical
processes are caused by chemical reaction (EC mechanism), as
no peaks were observed in the reverse scan. For the oxidation
peaks there were a few peaks of small intensities at the subsequent
cathodic sweep as a result of decomposition of the oxidized
species (Filipovic´ et al., 2017). Cyclic voltammograms of nitro
derivatives showed additional reduction and oxidation peaks.
Reduction peak at around−1.20V corresponds to reversible one-
electron reduction of the radical anion of the nitro group which
is commonly known in aprotic solvents (Silvester et al., 2006).
Since the intensities of the reverse scan currents are decreased the
mechanism of the reaction is also EC. Additional oxidation peak
at around −1.35V belongs to reversible one-electron oxidation
of imine group. The oxidation peak is invisible for compounds
from set 1 which means that the presence of strong electron
withdrawing nitro group enables oxidation of the anion (Fry and
Reed, 1969). The intensities of the reverse scan are increased by
20–30% implying the ECE nature of the reaction mechanism.
Peak currents were correlated with the square root of scan
rate (20–500mV s−1) and the linear relationship was obtained
which indicated diffusion controlled process on the electrode
surface.
DFT and Time-Dependent-DFT
Calculations
Electronic properties of investigated molecules were studied
using calculated energy of HOMO and LUMO orbitals and
HOMO–LUMO energy gap (Egap). All vertical excitation energies
were computed using B3LYP/6-31G(d,p) optimized ground-state
geometries in DMSO. Influence of substituents is estimated by
comparing the calculated frontier molecular orbital energies
(ELUMO, EHOMO) and Egap (Table 3). Molecular orbital plots
and energy levels of the HOMO, the LUMO and HOMO-
LUMO transitions of investigated compounds in DMSO are
depicted in Figure 5. The main difference between compounds
from set 1 and nitro-substituted (1,3-selenazol-2-yl)hydrazones
derives from the stabilization of LUMO in the presence of nitro
group. Different positions of nitro group on the phenyl ring
A cause certain changes in frontier molecular orbital energies.
As it is well known, electron acceptor group, such as nitro
group, adjacent to the aromatic ring decreases the electron
density on the ring through a resonance withdrawing effect. If
an acceptor is in a para or ortho position, certain stabilization
can be expected through the corresponding resonance forms.
The change in the position of the nitro group from para to
ortho andmeta destabilizes both HOMO and LUMO. A relatively
small increase in HOMO orbital energies can be negligible.
Destabilization of the LUMO by 0.1 eV when nitro substituent
changes position from para to ortho or meta, leads to an
increase of the energy gap. In all molecules with para and
ortho-nitro substituents, the LUMO are mainly located on the
aromatic rings A and hydrazone bridges. In the case of molecules
containing the nitro group in meta-position, the LUMO are
mainly located on the aromatic rings A with smaller participation
of the hydrazone bridges. The HOMO are located on selenazole
rings, phenyl rings B and hydrazone bridges (Figure 5). The
presence of electron donating substituents (–Me and –OMe)
on the phenyl rings B, destabilize HOMO and decrease the
energy gap. Since –OMe group is stronger electron donating
group in comparison to –Me group, selenazole analogs with
OMe substituted phenyl rings B have the smallest energy
gap.
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FIGURE 4 | Cyclic voltammograms of 1 and 2 (A) and 3 and 4 (B).
MAO A/B Inhibition Capacity
The main characteristics of neurodegenerative diseases are their
complex etiology and late onset. Currently available therapies
cannot stop progressive loss of function of neurons and can
provide just symptomatic relief. There is an urgent need for
discovery of novel chemical entities which can be used for
the treatment of neurodegeneration (Grottelli et al., 2016).
One of the strategies for the treatment of neurodegenerative
diseases is targeting MAOs, in particular MAO B in case of
Parkinson’s disease. These are enzymes, joined to the outer
membrane of mitochondria, which contain flavin adenine
dinucleotide (FAD). Two MAO isoforms, A and B, are encoded
by different genes. They have different distribution in tissues
and specificity for their substrates and inhibitors. Well known
MAO A substrates are serotonin, adrenaline and noradrenaline,
while this isoform is irreversible inhibited by clorgyline and
reversibly inhibited by moclobemide. MAO B substrates are β-
phenethylamine and benzylamine, while irreversible inhibition
is achieved by the MAO B selective antiparkinsonian drugs
TABLE 3 | Calculated energies of the HOMO and LUMO orbitals and energy gap
(in eV) for E-(1,3-selenazol-2-yl)hydrazones in DMSO obtained by TD/DFT method.
Compound ELUMO EHOMO Egap
1 −1.55 −5.34 3.79
1-Me −1.54 −5.30 3.76
1-OMe −1.53 −5.20 3.66
2 −2.71 −5.49 2.78
2-Me −2.71 −5.43 2.72
2-OMe −2.70 −5.31 2.61
3 −2.79 −5.51 2.72
3-Me −2.79 −5.45 2.66
3-OMe −2.79 −5.32 2.54
4 −2.67 −5.46 2.79
4-Me −2.67 −5.40 2.73
selegiline and rasagiline (Carradori and Silvestri, 2015). Notably,
MAOs regeneration process can yield the oxidative stress or
hydrogen peroxide, thus, inhibitors of MAOs might demonstrate
an indirect antioxidative and neuroprotective effect (Ramsay,
2016).
With the well-known representative phenelzine or iproniazid,
two hydrazine derivatives as non-selective MAO inhibitors are
used as antidepressants in the class of MAO inhibitors. Based on
that, numerous thiazol-2-ylhydrazones were developed to obtain
isoform-selective MAO inhibitors (for review see Carradori and
Silvestri, 2015), while related hydrazone-selenazoles have so far
not been investigated in this context to best of our knowledge.
Among thiazole derivatives, benzilydene-based (1,3-thiazol-2-
yl)hydrazones were the most active. Further enhancement of
their activity is achieved by the substitution at position 4 of the
1,3-thiazole nucleus. Additionally, presence of the aryl group at
C4 of the 1,3-thiazole ring allows the correct orientation of the
inhibitor inside the active site of enzyme close to the catalytic
FAD aromatic cage (Oncü Can et al., 2018). Consequently, we
investigated the MAO inhibition capacities of our structurally
related benzilydene-based (1,3-selenazol-2-yl)hydrazones. In a
pre-screening, we found most promising inhibition capacities for
compounds 1 and 4 with percental MAO inhibition >70% at a
concentration of 1µM (Table 4), while substitution on B phenyl
ring tend to results in reduced MAO inhibition potency for
these two representatives (e.g., 1 vs. 1-Me and 1-OMe). Further
more detailed characterization revealed nanomolar activity. The
most potent compound 4, bearing a meta nitro-group, showed
IC50 values of 73 nM (95% CI = [58, 93]) and 258 nM (95%
CI = [222, 301]) for MAO B and MAO A, respectively.
Surprisingly, compound 1 demonstrated highMAOB preference
(IC50= 252 nM, 95%CI= [173, 365]) with no inhibition ofMAO
A (IC50 > 10,000 nM).
In Vitro Antioxidant Capacity (AOC)
Since neurodegenerative diseases have complex and variable
underlying mechanisms, novel requirements for efficient
therapies include factors such as mitochondrial dysfunction,
neuroinflammation, and especially oxidative stress which have
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FIGURE 5 | Molecular orbital plots and energy levels of the HOMO, the LUMO, and HOMO-LUMO transitions of the benzylidene-based (1,3-selenazol-2-yl)
hydrazones in DMSO.
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TABLE 4 | Monoamine oxidase (MAO) A/B inhibition capacities of
benzylidene-based (1,3-selenazol-2-yl)hydrazones.
Compound % Inhibitiona (at 1µM)
MAO A MAO B
1 −6.8 ± 12.6 89.4 ± 1.5
1-Me 12.7 ± 3.5 23.4 ± 17.1
1-OMe 32.4 ± 3.3 33.0 ± 11.6
2 26.5 ± 3.7 64.8 ± 6.1
2-Me 17.2 ± 1.9 22.1 ± 8.7
2-OMe 28.0 ± 4.0 35.9 ± 11.2
3 32.7 ± 6.2 57.5 ± 11.4
3-Me 13.4 ± 2.4 7.4 ± 27.0
3-OMe 31.2 ± 1.6 23.8 ± 7.7
4 71.9 ± 3.5 96.3 ± 0.5
4-Me 22.1 ± 2.1 48.1 ± 2.9
4-OMe 49.4 ± 1.3 42.5 ± 19.0
aPercental inhibition calculated from remained enzyme activity normalized to control
(=100%). Values are given as means ± standard deviations (n = 2, global fit).
been identified as major determinants for their progress and
development. Consequently, an antioxidant drug development
strategy for neurodegenerative diseases has been of paramount
importance (Bautista-Aguilera et al., 2017).
Despite the fact that (thiazol-2-yl)hydrazones were
investigated in great extent as potential MAO inhibitors
and neurodegenerative drugs, only one recent study is dealing
with their antioxidant properties (Carradori et al., 2018).
On the other hand, results of comparative antioxidant study
on pyridine-based analogs of compounds from set 1 and their
sulfur isosters indicated greater free-radical scavenging activity of
(selenazol-2-yl)hydrazones in DPPH assay (Filipovic´ et al., 2017).
To get deeper insight on mechanism of AOC of investigated
compounds we investigated their radical scavenging activity, the
oxygen radical absorption capacity and reduction ability was
measured in a series of four in vitro tests (Table 5). The DPPH
assay is well known because of its ease and convenience for
testing of the free radical-scavenging activity of various synthetic
compounds. When an antioxidant scavenges these stable free
radical by hydrogen radical or electron donation the purple
DPPH assay solutions decolorized. ORAC test assay detects
decrease in fluorescence of fluorescein due to its oxidation by
a radical formed by the breakdown of AAPH over time (Ou
et al., 2001). Antioxidant suppresses this reaction by hydrogen
atom transfer. Trolox, a water soluble vitamin E analog, serves
as a positive control for quantification of antioxidant activity
present by its normalization to equivalent Trolox units. Since the
reducing power of a compound may be a good indication of its
possible antioxidant activity, the reduction of Fe(III) to Fe(II)
which results in Perl’s Prusian blue colored complex formation
(Oyaizu, 1986), as well as Mo(VI) to Mo(V) reduction with
formation of green colored phosphate/Mo(V) complex (Prieto
et al., 1999), were investigated in the presence of the tested
compounds.
TABLE 5 | Antioxidant capacity of investigated benzylidene-based
(1,3-selenazol-2-yl)hydrazones and the standard.
Compound IC50 (µM)
a EC50 (µM)
b TE
DPPH TAOC TRP ORAC
1 8.63 ± 1.66 648 ± 55 990 ± 92 0.75 ± 0.05
1-OMe 54.26 ± 4.54 548 ± 53 806 ± 85 0.74 ± 0.06
1-Me 45.06 ± 6.53 603 ± 61 966 ± 88 0.65 ± 0.07
2 21.9 ± 5.6 357 ± 41 390 ± 48 0.82 ± 0.07
2-OMe 40.5 ± 3.8 433 ± 39 560 ± 53 0.82 ± 0.07
2-Me 20.2 ± 4.3 416 ± 45 470 ± 41 0.77 ± 0.05
3 173.5 ± 11.6 325 ± 38 420 ± 45 0.90 ± 0.06
3-OMe 298.1 ± 14.8 632 ± 50 488 ± 46 0.86 ± 0.07
3-Me 151.6 ± 10.1 571 ± 45 480 ± 50 0.83 ± 0.05
4 44.8 ± 2.3 433 ± 43 376 ± 51 0.92 ± 0.08
4-OMe 79.2 ± 3.9 645 ± 53 398 ± 44 0.92 ± 0.07
4-Me 40.1 ± 4.7 579 ± 51 495 ± 48 0.92 ± 0.07
vitamin C 79.1 ± 1.8 140 ± 10 155 ± 39 0.97 ± 0.07
a IC50, concentration providing 50% of radicals scavenging activity.
bEC50, Concentration providing 0.500 of absorbance; The lower IC50 or EC50 value the
higher the antioxidant capacity; Values are given as means ± standard deviations (n = 3).
In our previous study pyridine-based analogs (HLSe1, HLSe2
and HLSe3) of compounds from set 1 were tested in DPPH
test and the activities were compared with vitamin C (Filipovic´
et al., 2017). Unsubstituted derivative HLSe1 appeared to be
the most active, while addition of –OMe and –Me substituents
resulted in less active species. The same trend was observed in
the case of their benzylidene-based analogs from set 1 (Table 5),
but with a significant difference in terms of activity. All three
derivatives showed significantly stronger free-radical scavenging
activity than vitamin C, especially 1, which was an order of
magnitude more active than the standard.
Addition of nitro group on the phenyl ring A reduced the
activity of 2, 4 and 4-OMe to some extent, while this effect
was the strongest for compounds from set 3 which is the only
series of compounds with lower activity than vitamin C. In all
three sets of compounds containing nitro group, the order of
activities changed fromH>Me>OMe (set 1) toMe>H>OMe
(sets 2–4), but activity of non-substituted and Me-derivatives
was almost the same in the case of ortho and para substitution.
Compounds 2-OMe, 2-Me and 4-Me are the only nitro group-
containing compounds which showed better activity than their
non-substituted analogs.
To the best of our knowledge ORAC, TAOC, and TRP tests
were performed for the first time for evaluation of AOC of some
1,3-selenazole based compounds. While observed activities in
TAOC and TRP tests were negligible (Table 5), activities of all
investigated compounds were greater than vitamin C in ORAC
test. Again, the series without nitro substituent showed the best
activity, but 1-Me appeared to be the most active compound.
Methyl derivatives showed the best activities in all three series.
In contrast to DPPH test, compounds having nitro group in ortho
position showed the weakest activities. Based on results presented
in Table 5 it was possible to establish simple structure-activity
relationship. The order of activities of compounds from the sets
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TABLE 6 | Antiproliferative activities of benzylidene-based (1,3-selenazol-2-yl)hydrazones.
Compound GI50 (µM)
A549 HBL-100 HeLa SW1573 T-47D WiDr BJ-hTert
1 28.0 ± 7.1 91 ± 12 41.0 ± 9.5 24 ± 8 6.4 ± 0.9 4.8 ± 0.8 n.d.
1-Me n.d.a n.d. n.d. 47 ± 3 n.d. n.d. n.d.
1-OMe n.d. n.d. n.d. 42.0 ± 7.7 n.d. n.d. n.d.
2 4.9 ± 1.5 21.0 ± 8.6 6.0 ± 0.7 5.3 ± 0.6 12.0 ± 1.5 5.0 ± 0.9 n.d.
2-Me 8.8 ± 2.2 95.0 ± 8.1 7.4 ± 1.4 4.6 ± 1.2 13.0 ± 1.3 8.2 ± 1.0 n.d.
2-OMe 22.0 ± 5.6 n.d. 49 ± 12 46 ± 10 36 ± 8.6 22.0 ± 2.3 n.d.
3 6.1 ± 0.8 28.0 ± 0.8 24.0 ± 7.1 16.0 ± 4.8 52 ± 13 40.0 ± 0.6 n.d.
3-Me 44 ± 15 60.0 ± 9.5 31.0 ± 4.0 18.0 ± 4.5 46.0 ± 9.7 55 ± 19 n.d.
3-OMe 52 ± 1 n.d. 26 ± 2 8.4 ± 0.2 67.0 ± 2.2 n.d. n.d.
4 16.0 ± 3.5 n.d. 31.0 ± 8.5 23.0 ± 1.2 6.3 ± 1.1 6.9 ± 1.3 n.d.
4-Me n.d. n.d. n.d. n.d. n.d. n.d. n.d.
4-OMe 16.0 ± 5.3 47 ± 13 33 ± 10 26 ± 17 66 ± 17 n.d. n.d.
5-fluorouracil n.d. 4.0 ± 0.7 15.0 ± 4.7 4.6 ± 1.5 47 ± 18 49.0 ± 6.7 5.5 ± 0.5
an.d, not determined (GI50 > 100µM).
is: set 1 > set 2 > set 3 > set 4, while in each set the order of
activity is Me> OMe>H.
Antiproliferative Effects
While 1,3-thiazoles are well known by their anticancer activity
(Ayati et al., 2015), their selenium analogs have been studied
in much less extent. To the best of our knowledge, there are
only two systematic anticancer activity studies of 1,3-selenazoles
(Zaharia et al., 2013; Zhao et al., 2013). Herein we performed the
in vitro antiproliferative activity of the benzilydene-based (1,3-
selenazol-2-yl)hydrazones on the following human solid tumor
cell lines: A549, HBL-100, HeLa, SW1573, T-47D and WiDr and
one normal human cell line BJ-hTert (Table 6).
In our study, 1 showedmoderate activity (GI50 = 10–100µM)
when tested against A549, HBL-100, HeLa and SW1573 cell lines,
and good activity (GI50 = 1–10µM) against T-47D andWiDr cell
lines. Substitution on B phenyl ring reduced activity in set 1 since
1-Me and 1-OMe were inactive (GI50 > 100µM) against five cell
lines. In contrast, the introduction of a nitro group in the phenyl
ring A significantly influenced the antiproliferative activity of 2–4
against A549, HBL-100, HeLa and SW1573 cells. The same trend
was observed for nitro analogs of 1-Me and 1-OMe on all six
cell lines with one exception. Namely, 4-Me remained inactive
against all six cell lines similarly to 1-Me. The most potent
compounds were 2 and 2-Me, which showed good activity against
A549, HeLa, SW1573 and WiDr cells. However, GI50 values
obtained on T-47D cell line were very close to 10µM. Also, a
good activity was noticed for 3 on A549 cells, 3-OMe on SW1573
cells and 4 against T-47D and WiDr cells. Some of the activities
exhibited by benzylidene-based (1,3-selenazol-2-yl)hydrazones
were comparable or even better than values obtained for positive
control 5-fluorouracil, the blockbuster anticancer drug. It is
worth to mention that in general all investigated compounds
showed selectivity toward tumor cell lines, since GI50 values for
non-transformed BJ-hTert cell line were not reached in the range
of applied concentrations (up to 100µM). Contrary, cytotoxic
activity on BJ-hTert cell of positive control 5-fluorouracil was in
low micromolar concentration range.
Prediction of Absorption, Distribution,
Metabolism, and Excretion (ADME)
Parameters and Pan Assay Interference
Compounds (PAINS) Evaluation
One of the main reasons for the frequent failure to develop drug-
like candidates is the risk of unwanted adverse side effects and
poor bioavailability in in vivo assays. To reduce the time and
cost of analysis of molecules without desirable pharmacokinetic
or pharmacodynamic profiles many in-silico platforms for
evaluation of number of physicochemical, pharmacokinetics
and medicinal chemistry properties have been developed
(Muller et al., 2017). The in-silico ADME profiles of the most
active compounds regarding MAO inhibition (1 and 4) and
antiproliferative activity (2 and 2-Me) were assessed through
robust SwissADME program and results are presented inTable 7.
All compounds shown desirable Lipinski rule principles like MW
≤ 500, number of atoms which act as hydrogen bond acceptors≤
10, number of hydrogen bond donors ≤ 5 and 1-octanol / water
partition coefficient (logPo/w ≤ 5) values (Lipinski et al., 2001).
Other physicochemical properties of the most active compounds,
such as number of rotatable bonds (≤ 10), molar refractivity
(from 40 to 130) and topological polar surface area (TPSA ≤ 140
Å2), were also found within the acceptable range. All compounds
are predicted to be highly absorbed by gastrointestinal (GI)
system after oral administration, while some of them are likely to
inhibit cytochrome P450 gene isoforms (i.e. CYP1A2, CYP219).
One of the most important parameters, a fundamental pre-
requisite for potential central nervous system (CNS) drugs, is
blood-brain barrier (BBB) permeation (Pajouhesh and Lenz,
2005). SwissADME predicted that 4, which showed MAO B
inhibition in a nanomolar concentration range, would not cross
BBB passively, while 1 is expected to be BBB accessible. However,
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TABLE 7 | Pharmacological profiles, medicinal chemistry principles and
lead-likeness properties of compounds 1, 4, 2 and 2-Me.
1 4 2 2-Me
PHYSICOCHEMICAL PROPERTIES
Molecular weight 326.25 371.25 371.25 385.28
#Heavy atoms 20 23 23 24
#Aromatic heavy atoms 17 17 17 17
Fraction Csp3 0 0 0 0.06
#Rotatable bonds 4 5 5 5
#H-bond acceptors 2 4 4 4
#H-bond donors 1 1 1 1
Molar Refractivity 84.09 92.91 92.91 97.88
Topological Polar Surface Area (TPSA-Å2) 37.28 83.1 83.1 83.1
ClogPo/w 2.07 1.54 1.54 1.82
PHARMACOKINETICS
GI absorption ++a ++ ++ ++
BBB permeant +b –c – –
Pgp substrate + – – –
CYP1A2 inhibitor – + + +
CYP2C19 inhibitor – + + +
CYP2C9 inhibitor – – – –
CYP2D6 inhibitor + – – –
CYP3A4 inhibitor – – – –
log Kp (cm/s) −5.98 −6.38 −6.38 −6.2
DRUGLIKENESS
Lipinski #violations 0 0 0 0
Ghose#violations 0 0 0 0
Veber#violations 0 0 0 0
Egan #violations 0 0 0 0
Muegge#violations 0 0 0 0
Bioavailability score 0.55 0.55 0.55 0.55
MEDICINAL CHEMISTRY
PAINS #alerts 0 0 0 0
Leadlikeness Yes Yes Yes Yes
Synthetic accessibility 3.63 3.62 3.71 3.81
a++ high; b+ activity; c– no activity.
based on Lipinski’s rules for CNS drugs (Pajouhesh and Lenz,
2005; Fernandes et al., 2016), 4 would be likely active in the
CNS. Relevant strategies for selection of molecules with preferred
drug-like profiles examined by SwissADME indicate that the
most active compounds represent drug candidates since they
possess important functional groups and bioavailability. Finally,
according to a recently published editorial by Aldrich et al.
(Aldrich et al., 2017), in order to remove suspicion of artificial
activity, in addition to SwissADME the compounds have been
evaluated by ZINC PAINS Pattern Identifier (Sterling and Irwin,
2015). Applied algorithms did not report our compounds as
potential PAINS or covalent inhibitors.
Docking Study
Most drugs on the market were developed according to “one-
target-one-disease” philosophy (Strebhardt and Ullrich, 2008)
TABLE 8 | Docking scores (kcal/mol) for compounds and co-crystallized ligands
in neurodegenerative and cancer related proteins.
Neurodegenerative targets 5wbx/KCNN1 4crt/MAO B
1 −8.5 −10.3
4 −8.4 −10.7
lig5wbx –7.7 −8.1
lig4crt −6.4 –8.4
Cancer targets 1ipb/EIF4E 4h2b/5-NT
2-Me −10.0 −9.2
2 −9.5 −9.0
lig1ipb –9.3 −10.3
lig4h2b −9.7 –9.9
Scores for co-crystallized ligands are shown in italic.
and despite notable successes of this approach, especially with
single gene disorders, multifactorial diseases such as cancer still
remain inadequately treated (Talevi, 2015). However, there are
many examples of approved anticancer drugs, initially developed
as single-targeting, but actually multi-targeting agents (Frantz,
2005; Yildirim et al., 2007). There is growing evidence that
treatment of complex disorders, such as neurodegenerative
disorders and cancer, is more likely to be effective through
simultaneous modulation of multiple targets, making multi-
target paradigm a relevant issue in the drug discovery process.
Because of all mentioned above, it is important to study multi-
targeting properties of novel bioactive compounds at the very
beginning of their development in order to get insight about
their ability to act against complex diseases by modulating
multiple targets. Among other methods for target identification,
the docking studies showed their significance in recent years
(Ferreira et al., 2015). In this work, we tested the binding
capacities of compounds that had the strongest inhibition
capacity to MAO B (1 and 4) to also bind into the small
conductance calcium-activated channel protein 1 (KCNN1),
since this is a novel target for the treatment of neurological
diseases through activation (Dolga et al., 2014). Also, for the
most active compounds in antiproliferative screening (2 and 2-
Me) docking to cancer related proteins, eukaryotic translation
factor 4E (EIF4E) (Lu et al., 2016) and 5′-nucleotidase (5-NT)
(Frasson Corbelini et al., 2015) was performed. The compounds
studied had stronger calculated binding scores than known
inhibitors, except for 5-NT where they were within 1 kcal/mol.
The results are shown in Table 8, with co-crystallized ligands’
values underlined.
In addition, the results show that compounds 1 and 4 have
good interactions inside the binding site of MAO B, as seen
in Figure 6A. It can be seen that 1 and 4 have a near perfect
overlap inside the binding site and theymake strong hydrophobic
and electrostatic interactions with residues in the binding site.
They also have a binding pose similar to that of the known
inhibitor ASS234 (Bautista-Aguilera et al., 2017). Figure 6B
shows that the co-crystallized ligand and both compounds 1 and
4 donate a hydrogen bond to residue Met 51 of the channel
protein KCNN1. In addition, AJY receives a hydrogen bond
from Lys 75. Hydrophobic residues participating in the binding
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FIGURE 6 | (A) Binding site of MAO B in white with co-crystallized ligand ASS234 ((E)-N-methyl-N-[[1-methyl-5-[3-[1-(phenylmethyl)
piperidin-4-yl]propoxy]indol-2-yl]methyl]prop-1-en-1-amine). (B) Binding site of KCNN1 small conductance calcium-activated potassium channel protein 1 in white
with co-crystallized ligand AJY; (3Z)-6-bromo-3-(hydroxyimino)-5-methyl-1,3-dihydro-2H-indol-2-one. In each case compounds 1 in cyan and 4 in magenta. Residues
forming interactions shown in stick, with hydrophobic interaction groups shown in pink, electrostatic interaction in green, and both hydrophobic and electrostatic in
orange. Hydrogen bonds shown as dashed lines; nitrogen in blue, oxygen in red, sulfur and selenium in yellow.
FIGURE 7 | (A) Binding site of eukaryotic translation factor 4E in white with co-crystallized ligand GTA; P1-7-methylguanosine-P3-adenosine-5′,5′-triphosphate. (B)
Binding site of 5′ nucleotidase in white with co-crystallized ligand 0XE; 5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl beta-D-glucopyranosiduronic acid; Baicalin. In
each case compounds 2-Me in cyan and 2 in magenta. Residues forming interactions shown in stick, with hydrophobic interaction groups shown in pink, electrostatic
interaction in green, and both hydrophobic and electrostatic in orange. Hydrogen bonds shown as dashed lines; nitrogen in blue, oxygen in red, sulfur and selenium in
yellow.
are Phe 19, Val 55, Phe 68, Met 71, Met 72, Phe 140, and Leu
480.
Figure 7A shows that both compounds 2-Me and 2 receive
hydrogen bonds from residues Trp 102, Arg 112, and His 200
from the binding site of EIF4E. Residues Trp 102 and Arg
112 participate also in pi-pi (as does Trp 56) and cation-pi
interactions, respectively, with the ligands. In addition, GTA
participates in hydrogen bonding with Gln 57, Trp 102, Glu
103, Arg 157, and Lys 162. Phe 417 and Phe 500 from the
binding site of 5-NT participate in pi-pi contacts with all
ligands, as it can be seen in Figure 7B. Arg 40 and Asn
499 donate hydrogen bonds to both 2-Me and to 2. Asn
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499 and Asp 506 also participate in nonpolar contacts to the
ligands.
CONCLUSIONS
Study of compounds from focused library of 12 benzilydene-
based (1,3-selenazol-2-yl)hydrazones in screening on MAO B
inhibition revealed that 1 and 4 possess IC50 values in nanomolar
concentration range. Docking studies showed that KCCN1 is
additional target for 1 and 4, which indicates their possible multi-
targeting properties for the treatment of neurodegenerative
disorders. Antiproliferative activity screening indicates that 2 and
2-Me are the most potent anticancer agents among investigated
compounds with better activity than that of the positive control
5-fluorouracil. Docking studies point to 5-NT and EIF4E as
possible cancer-related targets. All investigated compounds
showed significant antioxidant activities, better than vitamin C in
DPPH and ORAC assays. To conclude, our findings highlight the
pharmacophore suitability of benzylidene-based (1,3-selenazol-
2-yl)hydrazones as novel MAO B/KCNN1 targeting compounds
with excellent antioxidative properties. This class also possess
antiproliferative activity which may be attributed to their strong
binding to cancer related targets 5-NT and EIF4E. Our further
investigation will be focused on experimental work in order to
confirm multi-targeting hypothesis.
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